{
  "ticker": "TRU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958527",
  "id": "02958527",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0834",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krwlcpd037fv.pdf",
  "summary": "### Key Market Update Summary:  \n- **Uzbekistan regulatory approval secured** \u2013 Validation program in Tashkent to commence, precursor to national screening rollout.  \n- **Zimbabwe validation completion** \u2013 Scheduled for **21 July 2025**, enabling expansion of public screening program.  \n- **Vietnam program launch** \u2013 Screening of 260,000 women in Ho Chi Minh City starts **28 July 2025**; devices shipped.  \n- **First commercial order in India** \u2013 Purchase of **10 devices + 1,080 sensors** from Renovate Biologicals.  \n- **Clinical validation** \u2013 Peer-reviewed study confirms TruScreen\u2019s **superior sensitivity (86.4%) and specificity (74.4%)** vs. traditional methods (TCT/HPV).  \n\n*No capital raising, financials, or material structural changes disclosed.*",
  "usage": {
    "prompt_tokens": 2580,
    "completion_tokens": 178,
    "total_tokens": 2758,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:59:05.653585"
}